Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $3.3MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Ray Sumita | Chief Legal Compliance Officer | Aug 13 '26 | Option Exercise | $0.00 | 18,196 | $0 | 127,374 | Aug 17 06:22 PM |
| Ray Sumita | Chief Legal Compliance Officer | Aug 13 '26 | Sale | $30.09 | 8,829 | $265,628 | 118,545 | Aug 17 06:22 PM |
| Meluzio Michael Vincent | VP, Prin. Accounting Officer | Aug 13 '26 | Option Exercise | $0.00 | 13,647 | $0 | 54,589 | Aug 17 06:19 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.